Integra LifeSciences Holdings
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Integra LifeSciences Holdings met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share increased significantly.
Gross margins dropped, operating margins contracted, net margins grew.
Integra LifeSciences Holdings recorded revenue of $210.1 million. The 14 analysts polled by S&P Capital IQ expected sales of $211.4 million on the same basis. GAAP reported sales were 3.9% higher than the prior-year quarter's $202.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.85. The 14 earnings estimates compiled by S&P Capital IQ averaged $0.77 per share. GAAP EPS of $0.46 for Q3 were 18% higher than the prior-year quarter's $0.39 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 62.1%, 70 basis points worse than the prior-year quarter. Operating margin was 9.4%, 480 basis points worse than the prior-year quarter. Net margin was 6.3%, 70 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $216.9 million. On the bottom line, the average EPS estimate is $0.83.
Next year's average estimate for revenue is $834.5 million. The average EPS estimate is $3.04.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 157 members out of 169 rating the stock outperform, and 12 members rating it underperform. Among 55 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 53 give Integra LifeSciences Holdings a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Integra LifeSciences Holdings is outperform, with an average price target of $43.27.
- Add Integra LifeSciences Holdings to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Integra LifeSciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.